, Volume 203, Issue 4, pp 665–675 | Cite as

The effects of the selective 5-HT2C receptor antagonist SB 242084 on learned helplessness in male Fischer 344 rats

  • Paul V. StrongEmail author
  • Benjamin N. Greenwood
  • Monika Fleshner
Original Investigation



Rats exposed to an uncontrollable stressor demonstrate a constellation of behaviors such as exaggerated freezing and deficits in shuttle box escape learning. These behaviors in rats have been called learned helplessness and have been argued to model human stress-related mood disorders. Learned helplessness is thought to be caused by hyperactivation of serotonin (5-HT) neurons in the dorsal raphe nucleus (DRN) and a subsequent exaggerated release of 5-HT in DRN projection sites. Blocking 5-HT2C receptors in the face of an increase in serotonin can alleviate anxiety behaviors in some animal models. However, specific 5-HT receptor subtypes involved in learned helplessness remain unknown.


The current experiments tested the hypothesis that 5-HT2C receptor activation is necessary and sufficient for the expression of learned helplessness.


The selective 5-HT2C receptor antagonist SB 242084 (1.0 mg/kg) administered i.p. to adult male Fischer 344 rats prior to shuttle box behavioral testing, but not before stress, blocked stress-induced deficits in escape learning but had no effect on the exaggerated shock-elicited freezing. The selective 5-HT2C receptor agonist CP-809101 was sufficient to produce learned helplessness-like behaviors in the absence of prior stress and these effects were blocked by pretreatment with SB 242084.


Results implicate the 5-HT2C receptor subtype in mediating the shuttle box escape deficits produced by exposure to uncontrollable stress and suggest that different postsynaptic 5-HT receptor subtypes underlie the different learned helplessness behaviors.


5-HT2C receptor Learned helplessness Serotonin Depression Anxiety Uncontrollable stress Escape deficits Exaggerated freezing SB 242084 CP-809101 


  1. Abramowski D, Rigo M, Duc D, Hoyer D, Staufenbiel M (1995) Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera. Neuropharmacology 34:1635–1645CrossRefPubMedGoogle Scholar
  2. Abrams JK, Johnson PL, Hay-Schmidt A, Mikkelsen JD, Shekhar A, Lowry CA (2005) Serotonergic systems associated with arousal and vigilance behaviors following administration of anxiogenic drugs. Neuroscience 133:983–997CrossRefPubMedGoogle Scholar
  3. Amat J, Paul E, Zarza C, Watkins LR, Maier SF (2006) Previous experience with behavioral control over stress blocks the behavioral and dorsal raphe nucleus activating effects of later uncontrollable stress: role of the ventral medial prefrontal cortex. J Neurosci 26:13264–13272CrossRefPubMedGoogle Scholar
  4. Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S (2001) Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 4:399–408CrossRefPubMedGoogle Scholar
  5. Bilkei-Gorzo A, Gyertyan I, Levay G (1998) mCPP-induced anxiety in the light-dark box in rats—a new method for screening anxiolytic activity. Psychopharmacology (Berl) 136:291–298CrossRefGoogle Scholar
  6. Bromidge SM, Duckworth M, Forbes IT, Ham P, King FD, Thewlis KM, Blaney FE, Naylor CB, Blackburn TP, Kennett GA, Wood MD, Clarke SE (1997) 6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist. J Med Chem 40:3494–3496CrossRefPubMedGoogle Scholar
  7. Burghardt PR, Fulk LJ, Hand GA, Wilson MA (2004) The effects of chronic treadmill and wheel running on behavior in rats. Brain Res 1019:84–96CrossRefPubMedGoogle Scholar
  8. Burghardt NS, Bush DE, McEwen BS, LeDoux JE (2007) Acute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5-HT(2C) receptor antagonist. Biol Psychiatry 62:1111–1118CrossRefPubMedGoogle Scholar
  9. Campbell BM, Merchant KM (2003) Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. Brain Res 993:1–9CrossRefPubMedGoogle Scholar
  10. Clemett DA, Punhani T, Duxon MS, Blackburn TP, Fone KC (2000) Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology 39:123–132CrossRefPubMedGoogle Scholar
  11. Cornelio AM, Nunes-de-Souza RL (2007) Anxiogenic-like effects of mCPP microinfusions into the amygdala (but not dorsal or ventral hippocampus) in mice exposed to elevated plus-maze. Behav Brain Res 178:82–89CrossRefPubMedGoogle Scholar
  12. Drugan RC, Ryan SM, Minor TR, Maier SF (1984) Librium prevents the analgesia and shuttle box escape deficit typically observed following inescapable shock. Pharmacol Biochem Behav 21:749–754PubMedCrossRefGoogle Scholar
  13. Fanselow M, Lester L (1988) A functional behavioristic approach to aversively motivated behavior: predatory imminence as a determinant of the topography of defensive behavior. In: Bolles RC, Beecher MD (eds) Evolution and learning. Erlbaum, HillsdaleGoogle Scholar
  14. Gibson EL, Barnfield AM, Curzon G (1994) Evidence that mCPP-induced anxiety in the plus-maze is mediated by postsynaptic 5-HT2C receptors but not by sympathomimetic effects. Neuropharmacology 33:457–465CrossRefPubMedGoogle Scholar
  15. Graeff FG (2004) Serotonin, the periaqueductal gray and panic. Neurosci Biobehav Rev 28:239–259CrossRefPubMedGoogle Scholar
  16. Graeff FG, Silveira MC, Nogueira RL, Audi EA, Oliveira RM (1993) Role of the amygdala and periaqueductal gray in anxiety and panic. Behav Brain Res 58:123–131CrossRefPubMedGoogle Scholar
  17. Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF (1996) Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 54:129–141CrossRefPubMedGoogle Scholar
  18. Graeff FG, Viana MB, Mora PO (1997) Dual role of 5-HT in defense and anxiety. Neurosci Biobehav Rev 21:791–799CrossRefPubMedGoogle Scholar
  19. Grahn RE, Will MJ, Hammack SE, Maswood S, McQueen MB, Watkins LR, Maier SF (1999) Activation of serotonin-immunoreactive cells in the dorsal raphe nucleus in rats exposed to an uncontrollable stressor. Brain Res 826:35–43CrossRefPubMedGoogle Scholar
  20. Greenwood BN, Fleshner M (2008) Exercise, learned helplessness, and the stress-resistant brain. Neuromolecular Med 10:81–98CrossRefPubMedGoogle Scholar
  21. Greenwood BN, Foley TE, Day HE, Campisi J, Hammack SH, Campeau S, Maier SF, Fleshner M (2003) Freewheel running prevents learned helplessness/behavioral depression: role of dorsal raphe serotonergic neurons. J Neurosci 23:2889–2898PubMedGoogle Scholar
  22. Greenwood BN, Strong PV, Foley TE, Thompson RS, Fleshner M (2007) Learned helplessness is independent of levels of brain-derived neurotrophic factor in the hippocampus. Neuroscience 144:1193–1208CrossRefPubMedGoogle Scholar
  23. Greenwood BN, Strong PV, Brooks L, Fleshner M (2008) Anxiety-like behaviors produced by acute fluoxetine administration in male Fischer 344 rats are prevented by prior exercise. Psychopharmacology (Berl) 199:209–222CrossRefGoogle Scholar
  24. Griebel G (1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 65:319–395CrossRefPubMedGoogle Scholar
  25. Hackler EA, Turner GH, Gresch PJ, Sengupta S, Deutch AY, Avison MJ, Gore JC, Sanders-Bush E (2007) 5-Hydroxytryptamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation. J Pharmacol Exp Ther 320:1023–1029CrossRefPubMedGoogle Scholar
  26. Harada K, Aota M, Inoue T, Matsuda R, Mihara T, Yamaji T, Ishibashi K, Matsuoka N (2006) Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone. Eur J Pharmacol 553:171–184CrossRefPubMedGoogle Scholar
  27. Harada K, Yamaji T, Matsuoka N (2008) Activation of the serotonin 5-HT2C receptor is involved in the enhanced anxiety in rats after single-prolonged stress. Pharmacol Biochem Behav 89:11–16CrossRefPubMedGoogle Scholar
  28. Holmes A (2008) Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci Biobehav Rev 32:1293–1314CrossRefPubMedGoogle Scholar
  29. Jones N, Duxon MS, King SM (2002) 5-HT2C receptor mediation of unconditioned escape behaviour in the unstable elevated exposed plus maze. Psychopharmacology (Berl) 164:214–220CrossRefGoogle Scholar
  30. Kennett GA, Whitton P, Shah K, Curzon G (1989) Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur J Pharmacol 164:445–454CrossRefPubMedGoogle Scholar
  31. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemiss DN, Blackburn TP (1997) SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36:609–620CrossRefPubMedGoogle Scholar
  32. Li Q, Wichems CH, Ma L, Van de Kar LD, Garcia F, Murphy DL (2003) Brain region-specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice. J Neurochem 84:1256–1265CrossRefPubMedGoogle Scholar
  33. Lopez-Gimenez JF, Tecott LH, Palacios JM, Mengod G, Vilaro MT (2002) Serotonin 5- HT (2C) receptor knockout mice: autoradiographic analysis of multiple serotonin receptors. J Neurosci Res 67:69–85CrossRefPubMedGoogle Scholar
  34. Maier SF (1990) Role of fear in mediating shuttle escape learning deficit produced by inescapable shock. J Exp Psychol Anim Behav Processes 16:137–149CrossRefGoogle Scholar
  35. Maier SF (2001) Exposure to the stressor environment prevents the temporal dissipation of behavioral depression/learned helplessness. Biol Psychiatry 49:763–773CrossRefPubMedGoogle Scholar
  36. Maier SF, Seligman MEP (1976) Learned helplessness: theory and evidence. JEP: Gen 105:3–46Google Scholar
  37. Maier SF, Watkins LR (1998) Stressor controllability, anxiety, and serotonin. Cogn Ther Res 22:595–613CrossRefGoogle Scholar
  38. Maier SF, Watkins LR (2005) Stressor controllability and learned helplessness: the roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci Biobehav Rev 29:829–841CrossRefPubMedGoogle Scholar
  39. Maier SF, Grahn RE, Kalman BA, Sutton LC, Wiertelak EP, Watkins LR (1993) The role of the amygdala and dorsal raphe nucleus in mediating the behavioral consequences of inescapable shock. Behav Neurosci 107:377–388CrossRefPubMedGoogle Scholar
  40. Maier SF, Kalman BA, Grahn RE (1994) Chlordiazepoxide microinjected into the region of the dorsal raphe nucleus eliminates the interference with escape responding produced by inescapable shock whether administered before inescapable shock or escape testing. Behav Neurosci 108:121–130CrossRefPubMedGoogle Scholar
  41. Maier SF, Busch CR, Maswood S, Grahn RE, Watkins LR (1995a) The dorsal raphe nucleus is a site of action mediating the behavioral effects of the benzodiazepine receptor inverse agonist DMCM. Behav Neurosci 109:759–766CrossRefPubMedGoogle Scholar
  42. Maier SF, Grahn RE, Watkins LR (1995b) 8-OH-DPAT microinjected in the region of the dorsal raphe nucleus blocks and reverses the enhancement of fear conditioning and interference with escape produced by exposure to inescapable shock. Behav Neurosci 109:404–412CrossRefPubMedGoogle Scholar
  43. Maier SF, Amat J, Baratta MV, Paul E, Watkins LR (2006) Behavioral control, the medial prefrontal cortex, and resilience. Dialogues Clin Neurosci 8:397–406PubMedGoogle Scholar
  44. Martin JR, Ballard TM, Higgins GA (2002) Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol Biochem Behav 71:615–625CrossRefPubMedGoogle Scholar
  45. Maswood S, Barter JE, Watkins LR, Maier SF (1998) Exposure to inescapable but not escapable shock increases extracellular levels of 5-HT in the dorsal raphe nucleus of the rat. Brain Res 783:115–120CrossRefPubMedGoogle Scholar
  46. Menard J, Treit D (1999) Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci Biobehav Rev 23:591–613CrossRefPubMedGoogle Scholar
  47. Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:83–244CrossRefPubMedGoogle Scholar
  48. Millan MJ (2005) Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 60:441–460PubMedCrossRefGoogle Scholar
  49. Millan MJ, Brocco M, Gobert A, Dorey G, Casara P, Dekeyne A (2001) Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology 25:585–600CrossRefPubMedGoogle Scholar
  50. Molineaux SM, Jessell TM, Axel R, Julius D (1989) 5-HT1c receptor is a prominent serotonin receptor subtype in the central nervous system. Proc Natl Acad Sci USA 86:6793–6797CrossRefPubMedGoogle Scholar
  51. Murphy DL, Mueller EA, Garrick NA, Aulakh CS (1986) Use of serotonergic agents in the clinical assessment of central serotonin function. J Clin Psychiatry 47(Suppl):9–15PubMedGoogle Scholar
  52. Nunes-de-Souza V, Nunes-de-Souza RL, Rodgers RJ, Canto-de-Souza A (2008) 5-HT2 receptor activation in the midbrain periaqueductal grey (PAG) reduces anxiety-like behaviour in mice. Behav Brain Res 187:72–79CrossRefPubMedGoogle Scholar
  53. Oliveira LC, Broiz AC, de Macedo CE, Landeira-Fernandez J, Brandao ML (2007) 5-HT2 receptor mechanisms of the dorsal periaqueductal gray in the conditioned and unconditioned fear in rats. Psychopharmacology (Berl) 191:253–262CrossRefGoogle Scholar
  54. Pompeiano M, Palacios JM, Mengod G (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain Res 23:163–178CrossRefPubMedGoogle Scholar
  55. Rosenzweig-Lipson S, Sabb A, Stack G, Mitchell P, Lucki I, Malberg JE, Grauer S, Brennan J, Cryan JF, Sukoff Rizzo SJ, Dunlop J, Barrett JE, Marquis KL (2007) Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents. Psychopharmacology (Berl) 192:159–170CrossRefGoogle Scholar
  56. Santos JM, Martinez RC, Brandao ML (2006) Effects of acute and subchronic treatments with fluoxetine and desipramine on the memory of fear in moderate and high-intensity contextual conditioning. Eur J Pharmacol 542:121–128CrossRefPubMedGoogle Scholar
  57. Sharma A, Punhani T, Fone KC (1997) Distribution of the 5-hydroxytryptamine2C receptor protein in adult rat brain and spinal cord determined using a receptor-directed antibody: effect of 5,7-dihydroxytryptamine. Synapse 27:45–56CrossRefPubMedGoogle Scholar
  58. Singewald N, Sharp T (2000) Neuroanatomical targets of anxiogenic drugs in the hindbrain as revealed by Fos immunocytochemistry. Neuroscience 98:759–770CrossRefPubMedGoogle Scholar
  59. Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P, Marala R, Patterson T, Seymour PA, Swick A, Iredale PA (2007) CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 52:279–290CrossRefPubMedGoogle Scholar
  60. Takase LF, Nogueira MI, Bland ST, Baratta M, Watkins LR, Maier SF, Fornal CA, Jacobs BL (2005) Effect of number of tail shocks on learned helplessness and activation of serotonergic and noradrenergic neurons in the rat. Behav Brain Res 162:299–306CrossRefPubMedGoogle Scholar
  61. Wright DE, Seroogy KB, Lundgren KH, Davis BM, Jennes L (1995) Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain. J Comp Neurol 351:357–373CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Paul V. Strong
    • 1
    Email author
  • Benjamin N. Greenwood
    • 1
  • Monika Fleshner
    • 1
  1. 1.Department of Integrative Physiology and the Center for NeuroscienceUniversity of ColoradoBoulderUSA

Personalised recommendations